EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

PURPOSE: To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS: EV-101 is a phase I dose escalation/expansio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Jonathan, Sridhar, Srikala S., Zhang, Jingsong, Smith, David, Ruether, Dean, Flaig, Thomas W., Baranda, Joaquina, Lang, Joshua, Plimack, Elizabeth R., Sangha, Randeep, Heath, Elisabeth I., Merchan, Jamie, Quinn, David I., Srinivas, Sandy, Milowsky, Matthew, Wu, Chunzhang, Gartner, Elaina M., Zuo, Peiying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106979/
https://www.ncbi.nlm.nih.gov/pubmed/32031899
http://dx.doi.org/10.1200/JCO.19.02044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106979/
https://www.ncbi.nlm.nih.gov/pubmed/32031899
http://dx.doi.org/10.1200/JCO.19.02044

Ejemplares similares